Welcome to our dedicated page for RACB news (Ticker: RACB), a resource for investors and traders seeking the latest updates and insights on RACB stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RACB's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RACB's position in the market.
Research Alliance Corp. II (RACB) plans to redeem all outstanding Class A common stock shares effective December 2, 2022, pending stockholder approval. If approved during the special meeting, operations will cease, and the company will redeem shares at approximately $10.07 each, based on a trust account balance of about $150.7 million. After redemption, RACB intends to liquidate and dissolve, adhering to Delaware law. The company's sponsor has waived redemption rights for certain stocks, while a delisting process from NASDAQ will commence following the actions taken during the special meeting.
POINT Biopharma announced that the U.S. Nuclear Regulatory Commission has issued a Materials License for its new Indianapolis facility, allowing for the handling of nuclear materials. The 80,000-square-foot manufacturing center aims to be a leading radiopharmaceutical production site. This facility will support the Phase 3 clinical trial for metastatic castration resistant prostate cancer later this year. Additionally, POINT has a merger agreement with Research Alliance Corp. I, with plans to trade under the ticker symbol 'PNT' upon completion.
Research Alliance Corp. II (Nasdaq:RACB) has successfully completed its initial public offering, closing on March 22, 2021. The offering consisted of 14,950,000 shares of Class A common stock, including an over-allotment of 1,950,000 shares, priced at $10.00 per share. This resulted in gross proceeds of $149,500,000. Sponsored by RA Capital Management, the company aims to utilize these proceeds for business combinations within the healthcare sector. RACB shares began trading on Nasdaq on March 18, 2021.
FAQ
What is the market cap of RACB (RACB)?
